Q2 EPS Estimates for Cytokinetics Lowered by HC Wainwright

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities research analysts at HC Wainwright decreased their Q2 2025 earnings estimates for Cytokinetics in a research report issued on Wednesday, May 7th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings of ($1.47) per share for the quarter, down from their prior forecast of ($1.44). HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q3 2025 earnings at ($1.45) EPS, Q4 2025 earnings at ($1.52) EPS and FY2025 earnings at ($5.80) EPS.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, beating the consensus estimate of ($1.41) by $0.05. The company had revenue of $1.60 million during the quarter, compared to analyst estimates of $2.77 million. The firm’s quarterly revenue was up 89.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.33) EPS.

A number of other analysts have also recently weighed in on the company. Bank of America reduced their price target on Cytokinetics from $62.00 to $54.00 and set a “neutral” rating for the company in a research report on Tuesday, April 15th. Royal Bank of Canada reduced their target price on shares of Cytokinetics from $82.00 to $80.00 and set an “outperform” rating for the company in a research note on Wednesday. UBS Group reduced their price objective on shares of Cytokinetics from $47.00 to $41.00 and set a “neutral” rating for the company in a report on Friday, May 2nd. Stifel Nicolaus assumed coverage on Cytokinetics in a research note on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 price target on the stock. Finally, Morgan Stanley set a $67.00 target price on shares of Cytokinetics in a research note on Friday, March 7th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $74.44.

Cytokinetics Trading Down 2.4 %

NASDAQ:CYTK opened at $31.69 on Friday. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. Cytokinetics has a 52 week low of $31.67 and a 52 week high of $63.46. The stock’s 50 day moving average price is $40.18 and its 200 day moving average price is $45.96. The company has a market capitalization of $3.78 billion, a P/E ratio of -5.89 and a beta of 0.81.

Institutional Trading of Cytokinetics

A number of large investors have recently made changes to their positions in CYTK. Deep Track Capital LP lifted its holdings in Cytokinetics by 296.9% during the fourth quarter. Deep Track Capital LP now owns 2,500,000 shares of the biopharmaceutical company’s stock worth $117,600,000 after acquiring an additional 1,870,094 shares in the last quarter. Capital International Investors bought a new position in shares of Cytokinetics during the 4th quarter valued at about $51,564,000. T. Rowe Price Investment Management Inc. grew its position in shares of Cytokinetics by 11.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,752,123 shares of the biopharmaceutical company’s stock valued at $505,780,000 after purchasing an additional 1,062,136 shares during the period. Norges Bank bought a new stake in Cytokinetics during the 4th quarter worth approximately $46,556,000. Finally, Vestal Point Capital LP raised its holdings in Cytokinetics by 56.7% during the 4th quarter. Vestal Point Capital LP now owns 2,350,000 shares of the biopharmaceutical company’s stock worth $110,544,000 after buying an additional 850,000 shares during the period.

Insider Activity at Cytokinetics

In other news, Director Wendall Wierenga sold 20,000 shares of the company’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $38.46, for a total value of $769,200.00. Following the completion of the sale, the director now directly owns 24,848 shares of the company’s stock, valued at $955,654.08. This represents a 44.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $45.98, for a total transaction of $91,960.00. Following the transaction, the executive vice president now directly owns 116,071 shares in the company, valued at $5,336,944.58. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 95,362 shares of company stock worth $3,899,118. 2.70% of the stock is owned by insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.